SixPeaks Bio' chair Alex Mayweg (L) and CEO Philip Just Larsen
May 22, 2024 02:00 AM EDTUpdated 04:06 AM
Financing
Startups
Pharma

Ver­sant has a new obe­si­ty biotech. As­traZeneca has the op­tion to buy it

Kyle LaHucik

Senior Reporter

As­traZeneca is step­ping fur­ther in­to the obe­si­ty field with an op­tion for a fledg­ling start­up that seeks to pre­serve mus­cle mass, a com­mon con­cern for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times